Which FDA Class 2 clearance holders show repeat-filer signals in June 2026?
If you are screening FDA-visible companies for sourcing outreach, the short answer is: in Agence Octo’s June 2026 snapshot, the strongest repeat-filer signals in the filtered set came from a small top tier led by Epic Medical Pte. Ltd., Fisher & Paykel Healthcare, Ltd., and Unimed Medical Supplies, Inc., each with 9 cleared 510(k) submissions in the filtered set. This is an Agence Octo sourcing screen, not regulatory confirmation or proof of OEM fit.
A single FDA clearance is a datapoint.
A stack of clearances suggests a system.
That distinction matters if you are scouting OEM partners, white-label candidates, or platform companies in consumer health. In this June 2026 snapshot, Agence Octo applies the Agence Octo Repeat-Filer Screen: a simple sourcing lens for separating one-product visibility from signs of sustained filing activity. This is a sourcing signal, not regulatory confirmation. Every FDA-derived datapoint below is sourced from the FDA CDRH public database. Every category inference is Agence Octo Periscope methodology, not an FDA designation. Specifically, this article uses a filtered set of 86 companies in Agence Octo’s tracked consumer-health lenses, based on FDA CDRH 510(k) public records pulled on 2026-06-04; counts reflect cleared submissions visible in that snapshot, not all-time company activity. The “top 10” in this article refers to the 10 highest-count companies within that filtered set, ranked by visible cleared 510(k) submissions in the snapshot, with lens assignment and repeat-filer interpretation applied under Agence Octo methodology. One company in that top-10 set is not named in the source digest used for this article, so the list below is a partial named view of the top tier rather than a complete named top-10 roster.
What this snapshot shows
Bucket 1 — Official source: FDA CDRH public database, 510(k) clearances pulled 2026-06-04. Bucket 4 — Lens labels, repeat-filer interpretation, and sourcing inferences are Agence Octo Periscope methodology.
Within Agence Octo's tracked consumer-health lenses, 86 companies appeared in the filtered June snapshot. The top 10 highest-count companies in that set accounted for 65 cleared 510(k) submissions in total. Within those 65 clearances, the highest company-level counts were 9 each, held by Epic Medical Pte. Ltd., Fisher & Paykel Healthcare, Ltd., and Unimed Medical Supplies, Inc.
That does not prove commercial fit.
A company with repeated cleared submissions is not automatically the right manufacturing or partnership target. But repeated filings are a stronger sourcing signal than a single isolated clearance because they can suggest process continuity, product-family expansion, or both ([Agence Octo methodology]). In this article, “repeat-filer signals” means “showing repeat-filer signals in Agence Octo’s June 2026 screen,” not confirmed supplier readiness.
Core evidence table
| Evidence point | Value in this snapshot | Source / label |
|---|---|---|
| Filtered company set | 86 companies | FDA CDRH public database; Agence Octo filtered consumer-health lenses |
| Top group analyzed | 10 highest-count companies in the filtered set | Agence Octo methodology |
| Total cleared 510(k) submissions held by top 10 | 65 | FDA CDRH public database |
| Highest company-level count | 9 clearances | FDA CDRH public database |
| Companies tied at highest count | Epic Medical Pte. Ltd.; Fisher & Paykel Healthcare, Ltd.; Unimed Medical Supplies, Inc. | FDA CDRH public database |
| Named companies disclosed from the top 10 in this article | 9 named companies plus 1 unnamed company in the 5-clearance tier | Source digest used for this article; Agence Octo methodology |
| Lens grouping used in this article | Respiratory & Sleep; Rehab & Neurotech; Home Diagnostics; Wearable Biosensors | Agence Octo Periscope methodology |
The Agence Octo Repeat-Filer Screen
Use this as an observational sourcing screen, not a compliance judgment.
| Screen question | Why it matters | How to read it |
|---|---|---|
| Does the company hold more than one cleared 510(k) in the current snapshot? | Repeat activity suggests filing continuity | One clearance can be a one-off. Five or more can suggest a repeat operator in this screen ([Agence Octo methodology]). |
| Are the clearances clustered in one product lens? | Concentration can suggest a platform or deep specialization | A tight cluster in Respiratory & Sleep or Rehab & Neurotech is a stronger specialization signal than scattered filings ([Agence Octo methodology]). |
| Does the company appear to file across product variants, not just one SKU? | Variant depth can suggest line extension capability | Multiple related cannulas, masks, sensors, or wheelchairs can indicate repeatable product-family work ([Agence Octo methodology]). |
Framework takeaway: watch the stack, not any single signal.
A repeat filer is not automatically OEM-ready. But a repeat filer with category concentration and visible variant depth deserves a second look.
The repeat-filer group in this June 2026 snapshot
Bucket 1 — Official source: FDA CDRH public database. Bucket 4 — Lens labels and grouping are Agence Octo Periscope methodology.
The highest-volume repeat filers in the top 10 highest-count companies were:
- Epic Medical Pte. Ltd. — Singapore — 9 clearances — Rehab & Neurotech
- Fisher & Paykel Healthcare, Ltd. — New Zealand — 9 clearances — Respiratory & Sleep
- Unimed Medical Supplies, Inc. — Shenzhen, China — 9 clearances — Wearable Biosensors
- Cepheid — United States — 6 clearances — Home Diagnostics / Respiratory & Sleep
- Roche Molecular Systems, Inc. — United States — 6 clearances — Home Diagnostics / Respiratory & Sleep
- Sleepnet Corporation — United States — 6 clearances — Respiratory & Sleep
- Kunshan Hi-Fortune Health Products Co., Ltd. — China — 5 clearances — Rehab & Neurotech
- Abbott Molecular — United States — 5 clearances — Home Diagnostics
- Mölnlycke Health Care AB — Sweden — 5 clearances — Respiratory & Sleep
- An unnamed tenth company in the filtered top-10 set also fell within the 5-clearance tier in this snapshot — lens assignment under Agence Octo methodology
This is where the screen becomes useful.
A company with 5 to 9 clearances in a single snapshot can look less like a one-product event and more like an operator with an active filing rhythm ([Agence Octo methodology]). That does not tell you whether the company wants OEM relationships, white-label deals, or direct brand control. It does suggest the company is worth moving from passive watchlist to active research.
What stands out by lens
Bucket 1 — Official source: FDA CDRH public database. Bucket 4 — Category lens assignment is Agence Octo Periscope methodology.
Respiratory & Sleep dominated the named top group, with 7 companies represented if dual-lens assignments are included and the unnamed tenth company excluded from the lens count shown here.
That concentration matters.
It suggests this lens may have the deepest visible repeat-filer bench in the current snapshot. For sourcing teams, that can mean more operator density, more product-family overlap, and more competition for the same counterparties ([Agence Octo methodology]).
Rehab & Neurotech showed 3 companies in the top group, including Epic Medical Pte. Ltd. and Kunshan Hi-Fortune Health Products Co., Ltd.
Home Diagnostics appeared through US-based repeat filers including Cepheid, Roche Molecular Systems, and Abbott Molecular.
Wearable Biosensors had only one company in the named top group by count: Unimed Medical Supplies, Inc. That smaller count does not mean the lens is weak. It may mean the visible repeat-filer pool is narrower in this snapshot ([Agence Octo methodology]).
What stands out by geography
Bucket 1 — Official source: FDA CDRH public database.
The named companies in the top group broke down as follows:
- United States — 4 named companies
- China — 2 named companies
- Singapore — 1 named company
- New Zealand — 1 named company
- Sweden — 1 named company
- Unspecified in this article — 1 unnamed top-10 company
Geography does not prove business model.
US-based repeat filers may be brand-led, test-led, or vertically integrated operators. China- and Singapore-based repeat filers may include manufacturing-led, export-led, or partnership-capable operators. Those are practitioner-reported sourcing hypotheses under Agence Octo methodology, not FDA designations, and they should not be inferred from geography alone. The point is not to assume. The point is to know which companies merit deeper diligence first.
Three companies worth a second look
This is not a ranking of quality or safety.
It is a sourcing short list based on repeat-filer shape in the June snapshot.
- Unimed Medical Supplies, Inc. — 9 clearances from Shenzhen, China in Wearable Biosensors. Repeated filings alongside a Shenzhen location may be a useful sourcing signal to investigate, but any export or manufacturing-capability inference is Agence Octo methodology and should be verified through direct supplier diligence.
- Fisher & Paykel Healthcare, Ltd. — 9 clearances in Respiratory & Sleep. The visible concentration around respiratory products may suggest product-family continuity ([Agence Octo methodology]).
- Epic Medical Pte. Ltd. — 9 clearances in Rehab & Neurotech. The count alone places it in the highest-activity tier in this snapshot; any sourcing conclusion beyond that requires separate diligence.
What buyers should do with this list
Use this list to prioritize research, not to approve suppliers.
If a company is a repeat filer, concentrated in one lens, and visibly extending a product family, it has earned a deeper commercial review. That next review still needs ordinary sourcing work: ownership clarity, manufacturing role, export history, and channel fit. The clearance count gets the company onto the board. It does not close the deal.
Buyer checklist:
- Confirm the legal entity and operating location
- Verify whether the company is the brand owner, manufacturer, or both
- Check whether the cleared products align with your target category
- Look for product-family continuity across the visible clearances
- Validate export, quality, and channel fit through direct diligence
Agence Octo Periscope flags these patterns automatically — see Agence Octo Periscope in action.